BAL PHARMA LTD. Fair Value
BALPHARMA · Healthcare · Current price ₹85.59
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹48 | 8% ROE fading to 14% over ~3 yrs, on ₹52 book |
| Relative P/E | ₹119 | EPS × 30.3 peer-median P/E |
| Graham floor | ₹68 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is BAL PHARMA LTD. undervalued?
DocStoX estimates the fair value of BAL PHARMA LTD. at ₹71 per share, versus the current market price of ₹86. That puts the stock about -16.9% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹48), Relative P/E (₹119), Graham floor (₹68). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹48 (bear) to ₹71 (base) to ₹119 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on BAL PHARMA LTD.
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.